Eli Lilly's Weight-Loss Drugs Contribute Significantly to Revenue

In Q1 2026, Eli Lilly's Mounjaro and Zepbound generated $12.8 billion in revenue, accounting for nearly two-thirds of the company's total revenue. The drugs' growth rates continue to accelerate, with Mounjaro seeing a year-over-year increase of 125%.

By Daniel Sparks, The Motley Fool Mon, July 13, 2026 at 11:43 AM GMT+3 5 min read · Yahoo Finance · July 13, 2026, 08:43 UTC

Eli Lilly's Weight-Loss Drugs Contribute Significantly to Revenue

Tickers: $LLY $NVDA

Topics: investor_relations pharmaceuticals revenue_growth

Read the full article at Yahoo Finance

More World news

Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC
DPC Holdings PLC Reports Record Q3 Revenue Growth and Issues 2027 Financial Guidance Seeking Alpha · November 12, 2026, 19:01 UTC
Senate Minority Leader Schumer Demands Congressional Testimony from Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 18:59 UTC
Nvidia Shares Plunge Following CEO Jensen Huang's Departure Amid Investigation Motley Fool · November 12, 2026, 19:00 UTC
San Francisco Fed President Mary Daly Views AI as Transformative Investment Opportunity Seeking Alpha · November 12, 2026, 19:00 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC
The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC